Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.5% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) fell 4.5% during mid-day trading on Tuesday . The stock traded as low as $28.59 and last traded at $28.6750. 176,375 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 2,123,972 shares. The stock had previously closed at $30.04.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. UBS Group set a $50.00 price target on shares of Capricor Therapeutics in a research note on Monday, December 15th. B. Riley reissued a “buy” rating and set a $50.00 target price (up previously from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 22nd. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Finally, Maxim Group increased their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Trading Down 3.3%

The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -16.07 and a beta of 0.62. The company has a fifty day moving average price of $14.25 and a two-hundred day moving average price of $10.04.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). As a group, equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in Capricor Therapeutics by 6.8% during the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after purchasing an additional 61,701 shares in the last quarter. Woodline Partners LP grew its stake in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after buying an additional 99,384 shares in the last quarter. Pier Capital LLC raised its holdings in shares of Capricor Therapeutics by 35.0% in the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after buying an additional 128,837 shares during the period. Octagon Capital Advisors LP acquired a new position in Capricor Therapeutics during the 1st quarter worth about $4,270,000. Finally, Goldman Sachs Group Inc. lifted its stake in Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.